What Parquest Capital does

Parquest Capital is an independent French private equity firm founded in 2001 and headquartered in Paris at 19, Avenue de l'Opéra, regulated by the Autorité des Marchés Financiers as a Société de Gestion de Portefeuille under registration GP02-021. The firm specializes in mid-market investments in France with check sizes of €10M to €100M per transaction, concentrated across three preferred sectors: B2B Services, Software, and Health & Care. Across its 20+ year history, Parquest has executed 39 platform investments and 96 add-on acquisitions, deploying capital primarily through primary and secondary management buyouts, family business transfers, and acquisitions of non-strategic corporate subsidiaries.

The firm operates as a classic mid-market PE franchise: it sources proprietary deal flow through direct entrepreneur and intermediary relationships, invests alongside management teams, and supports portfolio companies through both organic growth and buy-and-build strategies. Revenue is generated through two streams: recurring management fees on committed fund capital (across Parquest I, II, and III) and performance-based carried interest crystallized at exit. The current flagship, Parquest III, closed at €414M in June 2024 and is classified as an SFDR Article 8 fund reflecting ESG integration commitments. The firm also runs an ESG integration framework across the investment lifecycle and a philanthropic fund launched in 2023.

Parquest's organizational footprint remains deliberately boutique, with approximately 20 professionals organized around the three sector verticals and support functions including investor relations, ESG, and finance. The senior team combines alumni of HEC, ESCP, École Centrale Paris, and prior roles at Boston Consulting Group, Bain & Company, McKinsey, JP Morgan, Goldman Sachs Asset Management, and prior PE firms. Notable long-term portfolio partnerships include Unither (since 2006, pharmaceutical contract manufacturing) and recent exits include Sopral (sold to IPN/CapVest in 2025), Aserti (sold to Chequers Capital in March 2026), and JVS (sold to CAPZA in October 2024).

Name

Parquest Capital

Legal name

Parquest

Website

https://parquest.fr/en

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Parquest Capital is an independent French private equity firm managing mid-market investments of €10M–€100M per deal across B2B Services, Software, and Health & Care, serving French SMEs and management teams through MBOs, family business transfers, and capital reinforcement via its Parquest fund series.

Ownership category

akta.pro rank

Product category

Private Equity Asset Management

NAICS

Other Financial Vehicles (525990), Nondepository Credit Intermediation (5222)

SIC

Miscellaneous Business Credit Institution (6159)

akta.pro primary industry

Secondary Venture Funds (VC Secondaries) (FSANAAAK)

akta.pro secondary industries

Private Equity Buyout Fund-of-Funds (FSANAGAD), Secondary Fund-of-Funds (FoF Secondaries) (FSANAGAB), Equity-Linked Liability Management (Buybacks/Tender Offers/Exchange Offers) (FSACAAAL), LP Secondaries — Growth Equity Funds (FSAHALAC)

Keywords

• Mid-market private equity
• Management buyout financing
• Private equity fund management
• Sector-focused equity investment
• Growth capital investment

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Management Fees: Asset management fees from managing private equity funds (Parquest I, II, and III funds)
2. Carried Interest: Performance-based carried interest on successful fund exits and portfolio company realizations

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Parquest Capital is an independent French private equity firm that invests €10M to €100M per deal in mid-market SMEs through primary and secondary management buyouts (MBOs), family business transfers, acquisitions of non-strategic subsidiaries, and capital strengthening transactions. The firm manages dedicated funds (Parquest I, II, III) targeting three preferred sectors: BtoB Services, Software, and Health & Care, providing equity capital, strategic support, and operational expertise to management teams across France.

Product overview

Parquest Capital is an independent French private equity firm specializing in mid-market SME investments. The firm does not offer a unified software product but rather manages investment funds and portfolio companies across three preferred sectors: B2B Services, Software, and Health & Care. Parquest III Fund (€414M raised in 2024, SFDR Article 8 classified) serves as the primary investment vehicle, targeting investments between €10M and €100M per deal. The firm's offering includes MBO transactions (primary and secondary), family business transfers, acquisition of non-strategic subsidiaries, and capital reinforcement programs. Beyond capital investment, Parquest provides ESG integration services throughout the investment lifecycle and operates a philanthropic fund supporting social causes.

Differentiator

Problem solved

Functional benefit

Products and services

• Parquest III Fund Parquest's third flagship investment fund, raised at €414 million in June 2024, classified as an SFDR Article 8 fund focused on sustainable finance. The fund targets French SMEs in the mid-market segment with investment sizes ranging from €10M to €100M per deal.
• BtoB Services Investment Vertical Investment vertical focused on B2B services companies, with portfolio including engineering consulting (Betem Groupe), electrical services (Fauché), receivables management (FDI), claims management (Polyexpert), business intelligence (ADIT), specialty chemicals distribution (Safic Alcan), aerial work platform rental (Accès Industrie), and repair/maintenance services (Aserti).
• Software Investment Vertical Investment vertical focused on software companies, with portfolio including management software for local authorities (JVS), SaaS ERP solutions for home care, law firms, and SMEs (Xelya), financial consolidation and reporting software (Amelkis), and Atlassian consulting services (Spectrum Groupe).
• Health & Care Investment Vertical Investment vertical focused on healthcare and life sciences companies, with portfolio including pharmaceutical manufacturing (Unither), private clinics (Vivalto Santé, 5 Santé), homecare services (Homeperf), private education (Eduservices, Vitalliance), radiology services (Imaneo), and nutritional solutions (Sopral).
• ESG Integration Services Environmental, Social, and Governance integration across the investment lifecycle, including pre-investment due diligence, holding phase support for portfolio companies in defining ESG strategy and monitoring KPIs, and exit valuation of ESG achievements.
• Parquest Philanthropic Fund Philanthropic fund launched in 2023, hosted by Transatlantic Bank's endowment fund, providing annual financial support and pro bono skills sharing to 6-8 projects focused on social inclusion, fighting inequality, and climate change, with grants ranging from €10,000 to €30,000 per project.

Quantifiable outcome

• 39 investments completed over fund history
• +3 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• Initiative Climat International (iCI)coreStrategic or Co-development Partner · 1 January 2021Parquest signed the iCI charter in 2021, committing to climate-related investment practices and transparency.
• KorianminorStrategic or Co-development Partner · 1 February 20205 Santé was sold to Korian in 2020 as part of an exit strategy. Korian is a European specialist in age-related care services.
• Groupe Avril / SofiproteolcoreStrategic or Co-development Partner · 30 November 2018Parquest acquired Sopral from Groupe Avril. Sofiproteol (Avril's financing subsidiary) became a minority shareholder alongside Parquest and management, continuing to support Sopral's development.
• France InvestcoreStrategic or Co-development Partner · 1 January 2015Parquest is a signatory of France Invest's charter of investor commitment for growth (signed 2008), charter on gender parity (signed 2020), and charter on value sharing (signed 2023). France Invest is the French private equity and venture capital association.
• PRI (Principles for Responsible Investment)coreStrategic or Co-development Partner · 1 January 2015Parquest signed the UN PRI in 2015, committing to incorporate ESG criteria into investment analysis and decision-making processes.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Activa Capital: Independent French mid-market private equity firm investing in SMEs. Direct comparable to Parquest given similar French focus, mid-market deal size, and multi-sector approach; has co-invested with Parquest on transactions such as Mont Blanc-Materne.
• Siparex: Independent French mid-market private equity firm with regional presence. Direct comparable to Parquest in French SME buyouts and growth capital transactions, competing for similar deal flow.
• Naxicap Partners: French mid-market private equity firm (subsidiary of Natixis) investing in French SMEs with comparable deal sizes and sector focus. Direct competitor for French mid-market opportunities and LP capital.
• Equistone Partners Europe: European mid-market private equity firm. Supported Unither alongside Parquest, evidencing comparable mid-market European focus and willingness to co-invest in French SMEs.
• LBO France: One of France's leading independent mid-market private equity firms with similar size and sector breadth. Direct comparable to Parquest in mid-market French SME buyouts across BtoB services, healthcare, and software verticals.
• Omnes Capital: French private equity firm with mid-market and growth focus. Co-led the Vivalto Santé investment with Parquest in 2009, evidencing overlap in healthcare investing and shared deal structuring.
• EMZ Partners: European mid-market private equity firm. Acquired Fauché from Parquest alongside management in 2021, evidencing direct interaction in French mid-market exits and similar fund size.
• Initiative & Finance: Independent French private equity firm focused on mid-market SMEs. Direct comparable to Parquest with similar deal size range, French geographic focus, and multi-sector expertise.
• CAPZA: Independent European private investment platform active in mid-market. Took over Parquest's JVS stake in 2024 and co-invested alongside Parquest in Advens, evidencing direct overlap in French mid-market deal flow.

Broad incumbents

• Bpifrance: French sovereign-backed investment bank and fund manager. Co-invested alongside Parquest in JVS and Sopral as a minority partner, making it a direct co-investor with structural advantages in capital cost and deal access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/parquest-capital

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A18 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parquest Capital